Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 2012

View Archived Issues

Orion discloses new androgen receptor antagonists

Novel nicotinic acetylcholine receptor ligands synthesized at CNRS and INSERM

Niacin analogue ARI-3037-MO evaluated in healthy subjects

GSK-1292263 markedly reduces lipids in nondiabetic subjects

European Institute of Oncology and University of Pisa sign oncology agreement

Dainippon Sumitomo Pharma and Shionogi to launch Aimix in Japan

Teriflunomide approved in Australia for multiple sclerosis

Votrient now available in Japan

Preclinical pharmacokinetics and efficacy of a potent MEK inhibitor presented

Novartis launches Sosei's inhalation capsule for COPD in Japan

FDA approves first cell culture-produced seasonal influenza vaccine

MedWell presents promising preclinical results for a novel drug candidate

Joyant Pharmaceuticals presents novel agents for cancer

Canadian group patents new androgen receptor ligands

FDA accepts resubmission of Levadex NDA

TRIM28 as a potential biomarker of high risk colorectal cancer

Gilead Sciences discloses novel agents for AIDS

Emory University and Wake Forest University synthesize new NET ligands

Neuren completes phase I NNZ-2566 study and files phase II IND

Study of alpha-1-antitrypsin drug shows efficacy and safety in type 1 diabetes

Basilea begins new phase I study of BAL-30072

Korean researchers patent novel agents for viral infections

Nihon Medi-Physics files for approval of NMA-78 in Japan

Cardio3 BioSciences gains clearance for phase III trial of regenerative heart failure therapy

ERYtech Pharma grants exclusive European rights for anticancer product to Orphan Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.